TinyGemsBreaks Archive - Page 28 of 125

MondayApr 15, 2024 1:37 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Represents Opportunity to Provide Solution for GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company advancing its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization, recently appointed Amy Mahery to its board of directors. “A biotech commercialization leader, Ms. Mahery has built an illustrious career that spans more than 20 years. During this period, she has gained commercial expertise working with small and large companies in common and rare conditions, as well as across several therapeutic areas… Ms. Mahery lauded CNS Pharmaceuticals and its efforts to fill gaps in areas with high unmet medical needs, such as glioblastoma multiforme (‘GBM’) treatment, saying,…

ThursdayApr 11, 2024 3:00 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Leveraging Strategic Integrations to Unlock Continued Opportunities

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a technology company developing solutions to optimize and automate the supply chain process and freight logistics, continues to be a marketplace partner with Geotab, a prominent company in the technology and logistics industry. “Fr8Tech announced last September that it had integrated its Fr8App freight-matching platform with Geotab’s open application programming interface (‘API’). According to the company, this integration was intended not only to boost substantially real-time visibility and efficiency for carriers and shippers but also to ensure that clients enjoy added capabilities through the Fr8App platform. The integration exemplifies Fr8App’s continuous improvement and Fr8Tech’s investment…

TuesdayApr 09, 2024 3:43 pm

TinyGemsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Moves Closer to Industrialization of E-Motion(TM) Product

Vision Marine Technologies Inc. (NASDAQ: VMAR), a leader in electric marine propulsion, today announced a groundbreaking achievement in electric outboard propulsion, in collaboration with McLaren Engineering, a division of Linamar Corporation. Aligning with the fast-evolving electric market and the upcoming SAE J1228 outboard compliance standard, Vision Marine has revolutionized the measurement of rated power output with its E-Motion(TM) 180E Electric Powertrain Systems. Vision Marine and McLaren Engineering have developed a sophisticated test cell, designed to meticulously control various critical parameters and provide a comprehensive and precise assessment of the powertrain system under conditions that mimic real-world usage. “We are excited…

TuesdayApr 09, 2024 2:23 pm

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Closes on $3.2M Public Offering

Flora Growth (NASDAQ: FLGC), a cannabis-focused consumer-packaged goods leader and pharmaceutical distributor serving all 50 states and 28 countries with 20,000-plus points of distribution around the world, has closed on an underwritten public offering. The offering, which was comprised of 1.7 million common shares, resulted in $3.23 million in gross proceeds for Flora Growth, before deductions. Flora Growth plans to use the funds from the offering for general corporate and working capital needs. Aegis Capital Corp. acted as the sole book-running manager for the offering, which closed on April 8, 2024. In addition, the company announced that its CEO, Clifford…

MondayApr 08, 2024 3:06 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Streamlines Operations to Focus on Commercial Segment

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that the company has initiated significant cost reduction and consolidation measures, aligning budget to current conditions. Actions are expected to drive an estimated $170 million reduction in Mullen’s operating and investing cash flow expenses over the next 12 months when compared to operating and investing cash flows for the 12 months ended Sept. 30, 2023. The company is making these changes to refine business operations and better align focus on the commercial EV segment that has opportunity to drive near term revenue for Mullen, including projected April sales…

ThursdayApr 04, 2024 3:15 pm

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Delivers Significant Growth to Top Line Revenue

Knightscope (NASDAQ: KSCP), an innovator in robotics and artificial intelligence (“AI”) technologies focused on public safety, is celebrating its 11th anniversary of its founding in 2013 with a total of 18 contracts for new business along with five renewal agreements valued at over $1 million. “Building on the success of its first Innovation Week and the recently announced 2023 Financial Performance Highlights, Knightscope delivers significant growth to its top line revenue with these latest contracts. Fast-growing markets such as transportation, healthcare, education and local government represent the majority of these contracts and account for many more future opportunities to expand…

ThursdayApr 04, 2024 2:22 pm

TinyGemsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Marks Strategic Milestone in Industrialization of High-Tension Battery Packs

Vision Marine Technologies Inc. (NASDAQ: VMAR), a leader in electric marine propulsion, today announced the commissioning of its partner Neogy, a subsidiary of Startek Energy Group, state-of-the-art lithium battery production facility in Pompignac, France. According to the announcement, this pivotal development marks a significant milestone in the industrialization of high-tension battery packs designed specifically for Vision Marine’s innovative electric boating solutions. “The use of HV batteries in the nautical industry demands a very high level of safety and mastery of the technology,” said Xavier Montagne, CTO of Vision Marine. “It’s not just a matter of designing the right battery but…

TuesdayApr 02, 2024 3:56 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives New Epilepsy, Anti-Viral Agent Patents

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received three new patent awards. According to the announcement, the company was awarded two new patents in its epilepsy patent family; both awards were granted in the United States. The U.S. patents, which cover both swallowed capsules and dissolvable oral tablets, complement research indicating DehydraTECH-CBD has potential to decrease epileptic seizures in rodents and to be absorbed into the bloodstream more effectively than the current treatments. In addition, Lexaria was awarded a patent in Japan in is antiviral agent patent family. The new patents bring the total of…

TuesdayApr 02, 2024 3:14 pm

TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Enters Acquisition Agreement to Acquire Biodefense Vaccine Developer

Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF). Appili is a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. According to the agreement, Adivir Inc., a wholly owned subsidiary of Aditxt, will acquire all issued and outstanding Class A common shares of Appili. Assets acquired by Aditxt will include FDA-approved LIKMEZ(TM), which is the ATI-1701 tularemia vaccine defense program, and the ATI-1801 topical formulation. “The acquisition of Appili would represent another step in Aditxt’s journey towards…

TuesdayApr 02, 2024 1:47 pm

TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing Genprex’s non-viral Oncoprex(R) Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer (“NSCLC”) in a humanized mouse model. “These positive preclinical data are very encouraging and support NPRL2 gene therapy as a potential treatment for a sub-group of NSCLC in which patients traditionally are resistant to existing therapies,” said Rodney Varner, president, chairman and CEO at Genprex. “We…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks